Neutralizing Antibodies in COVID-19 Patients and Vaccine Recipients after Two Doses of BNT162b2BNT162B2의 2 회 용량 후 COVID-19 환자 및 백신 수용자의 중화 항체Article Published on 2021-07-142022-09-01 Journal: Viruses [Category] SARS, 진단, [키워드] All participants analyzed anti-SARS-CoV-2 antibodies anti-SARS-CoV-2 antibody BNT162b2 Complete Covid patients COVID-19 COVID-19 patient COVID-19 patients Diagnosis dose dose regimen first dose generate Humoral response individual infected individual infected individuals long-term kinetics mild patient NAb nAb response NAb titer NAbs neutralization test Neutralizing antibodies neutralizing antibody neutralizing capacity of BNT162b2 P -value participant Participants Patient positive protective immunity pseudovirus recipient recipients remained SARS-CoV-2 second dose serology assays significantly higher surrogate virus neutralization test sVNT vaccinated individuals Vaccine virus neutralization test VNT [DOI] 10.3390/v13071364 PMC 바로가기 [Article Type] Article
Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of Remdesivir, a SARS-CoV-2 Replication InhibitorSARS-CoV-2 복제 억제제인 렘데시비르의 약동학, 약력학 및 약물 상호작용 프로필Review Published on 2021-05-012022-09-11 Journal: Clinical pharmacokinetics [Category] SARS, 치료기술, 치료제, [키워드] accumulate Activation acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 administration Analysis approval approvals Cell children Clinical data clinical dosing clinically Concentration coronavirus coronavirus disease Coronavirus disease 2019 country COVID-19 dose dose regimen doses drug-drug interaction Drug-drug interactions eliminated enzyme followed by GS-441524 healthy healthy volunteers Hospitalized in vitro inducer infected with COVID-19 inhibitor inhibitors intravenous Intravenous administration linear Loading dose maintenance dose metabolite mononuclear cells multiple dose multiple doses nucleoside once daily parenteral route Participants Patient patients with COVID-19 Peripheral blood Peripheral blood mononuclear cells Pharmacodynamic pharmacokinetic pharmacokinetics Phase I plasma polymerase predicted profile rationale RDV regimen Remdesivir Replication Result Ribonucleic acid SARS-CoV-2 severe acute respiratory syndrome Coronavirus severe coronavirus disease therapeutic Treatment treatment of COVID-19 triphosphate Veklury was selected [DOI] 10.1007/s40262-021-00984-5 PMC 바로가기 [Article Type] Review